SCHEMBL1490844

SCHEMBL1490844

NS(=O)(=O)c1ccc(B(O)O)cc1N1CCCC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.41
HSD17B10 Q99714 3/20 0.41
ALDH1A1 P00352 2/20 0.41
USP2 O75604 1/20 0.41
LMNA P02545 1/20 0.41
HPGD P15428 1/20 0.41
SLC6A4 P31645 1/20 0.41
HIF1A Q16665 1/20 0.41
MAPT P10636 2/20 0.40
MMP2 P08253 1/20 0.39
RAB9A P51151 1/20 0.35
SLC9A1 P19634 1/20 0.35
MEN1 O00255 1/20 0.35
THRB P10828 1/20 0.35
ALOX15 P16050 1/20 0.35
GFER P55789 1/20 0.35
YWHAG P61981 1/20 0.35
KMT2A Q03164 1/20 0.35
GAA P10253 2/20 0.34
HTT P42858 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6797103 0.76 ALDH1A1 (0.50) KDM4EHSD17B10ALDH1A1USP2LMNA
SCHEMBL6801445 0.75 ALDH1A1 (0.53) KDM4EHSD17B10ALDH1A1USP2LMNA
SCHEMBL28025003 0.74 ALDH1A1 (0.46) KDM4EHSD17B10ALDH1A1USP2LMNA
SCHEMBL4048066 0.74 CDC7 (0.56) KDM4EHSD17B10ALDH1A1MAPTRAB9A
SCHEMBL4059759 0.72 CA2 (0.50) KDM4EHSD17B10ALDH1A1USP2LMNA
SCHEMBL2558539 0.70 PDIA6 (0.47) KDM4EALDH1A1LMNAL3MBTL1CA1
SCHEMBL26613496 0.70 CA2 (0.41) KDM4EALDH1A1CA12CA1CA2
SCHEMBL18706439 0.69 ALDH1A1 (0.51) KDM4EALDH1A1LMNAHPGDMAPT
SCHEMBL31527700 0.69 KEAP1 (0.52) KDM4EHSD17B10ALDH1A1USP2LMNA
Hydrochloric Acid SCHEMBL11538427 0.69 KEAP1 (0.52) KDM4EHSD17B10ALDH1A1USP2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7897609-B2 Aryl substituted imidazonaphthyridines 3M INNOVATIVE PROPERTIES COMPANY (US) 2011-03-01 US disclosed
US-20070219228-A1 Aryl substituted imidazonaphthyridines 3M INNOVATIVE PROPERTIES COMPANY 2007-09-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070219228-A1 Aryl substituted imidazonaphthyridines IL2, IRF3, EIF2AK2 KDM4E 3178/4885HSD17B10 3367/4885ALDH1A1 1178/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.